Fig. 8.
Human DEC therapy (1 × 106 and 5 × 106) improves skeletal muscle strength at 180 days after systemic-intraosseous administration to the mdx/scid mice. (A) At 180 days after DEC transplant the ex vivo Aurora muscle test identified a significant increase of maximum stretch-induced contraction of the gastrocnemius muscle in both DEC-injected groups compared to the vehicle-injected controls. Data presented as mean ± SEM; Aurora Scientific in vitro Muscle Test System. * p < 0.05. (B) Grip strength analysis at 180 days after systemic-intraosseous administration of DEC therapy revealed improved grip strength between 5–10 weeks follow-up period in both DEC-injected groups compared to the vehicle-injected controls, and significant grip strength improvement at 9-weeks in 1 × 106 DEC-injected group when compared to the vehicle- injected control. **p < 0.01. Data presented as mean ± SEM